YieldMax™ Launches Option Income Strategy ETF on Moderna (MRNA)


CHICAGO, MILWAUKEE and NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- YieldMax™ announced the launch today of the following ETF:

MRNY seeks to generate monthly income via a synthetic covered call strategy on Moderna, Inc. (MRNA). The ETF is actively managed by ZEGA Financial. MRNY does not invest directly in MRNA.

MRNY is the newest member of the growing YieldMax™ ETF family and, like all YieldMax™ ETFs, aims to deliver substantial monthly income to investors. Please see table below for distribution and yield information for all outstanding YieldMax™ ETFs.

ETF
Ticker
1
ETF NameReference
Asset
Distribution
Rate
2,4
30-Day SEC
Yield
3
TSLYYieldMax™ TSLA Option Income Strategy ETFTSLA59.80%4.65%
OARKYieldMax™ Innovation Option Income Strategy ETFARKK32.62%4.97%
APLYYieldMax™ AAPL Option Income Strategy ETFAAPL30.89%4.55%
NVDYYieldMax™ NVDA Option Income Strategy ETFNVDA38.34%4.48%
AMZYYieldMax™ AMZN Option Income Strategy ETFAMZN39.00%4.61%
FBYYieldMax™ META Option Income Strategy ETFMETA26.49%4.43%
GOOYYieldMax™ GOOGL Option Income Strategy ETFGOOGL22.96%4.11%
NFLYYieldMax™ NFLX Option Income Strategy ETFNFLX34.82%5.00%
CONYYieldMax™ COIN Option Income Strategy ETFCOIN74.61%4.19%
MSFOYieldMax™ MSFT Option Income Strategy ETFMSFT16.17%4.17%
DISOYieldMax™ DIS Option Income Strategy ETFDIS15.68%3.92%
XOMOYieldMax™ XOM Option Income Strategy ETFXOM18.26%4.04%
JPMOYieldMax™ JPM Option Income Strategy ETFJPM15.80%0.00%
AMDY*YieldMax™ AMD Option Income Strategy ETFAMD
PYPY*YieldMax™ PYPL Option Income Strategy ETFPYPL
SQY*YieldMax™ SQ Option Income Strategy ETFSQ


 *   The inception date for AMDY is September 18, 2023. The inception date for PYPY is September 25, 2023. The inception date for SQY is October 10, 2023.
 1   All YieldMaxETFs have a gross expense ratio of 0.99%.
 2   The Distribution Rate is the annual yield an investor would receive if the most recently declared distribution, which includes option income, remained the same going forward. The Distribution Rate is calculated by multiplying such distribution by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV. The Distribution Rate represents a single distribution from the ETF and does not represent its total return. Distributions may also include a combination of ordinary dividends, capital gain, and return of investor capital, which may decrease an ETF’s NAV and trading price over time. As a result, an investor may suffer significant losses to their investment. These Distribution Rates may be caused by unusually favorable market conditions and may not be sustainable. Such conditions may not continue to exist and there should be no expectation that this performance may be repeated in the future.
   The 30-Day SEC Yield represents net investment income, which excludes option income, earned by such ETF over the 30-Day period ended September 30, 2023, expressed as an annual percentage rate based on such ETF’s share price at the end of the 30-Day period.
4  Each ETF’s strategy will cap potential gains if its reference asset’s shares increase in value, yet subjects an investor to all potential losses if the reference asset’s shares decrease in value. Such potential losses may not be offset by income received by the ETF.


Standardized Performance

For TSLY, click here. For OARK, click here. For APLY, click here. For NVDY, click here. For AMZY, click here. For FBY, click here. For GOOY, click here. For NFLY, click here. For CONY, click here. For MSFO, click here. For DISO, click here. For XOMO, click here. For JPMO, click here.

Prospectus

For TSLY, APLY, NVDY, AMZY, FBY, GOOY, NFLY, CONY and SQY, click here. For OARK, click here. For MSFO, DISO, XOMO, JPMO, AMDY, PYPY and MRNY, click here.

The performance data quoted above represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted above. Performance current to the most recent month-end can be obtained by calling (833) 378-0717.

Tidal Financial Group is the adviser for all YieldMax™ ETFs and ZEGA Financial is their sub-adviser.

About Tidal Financial Group

Formed by ETF industry pioneers and thought leaders, Tidal Financial Group sets out to revolutionize the way ETFs have historically been developed, launched, marketed and sold. With a focus on growing AUM, Tidal offers a comprehensive suite of services, proprietary tools, and methodologies designed to bring lasting ideas to market. Tidal is an advocate for ETF innovation. The firm is on a mission to provide issuers with the intelligence and tools needed to efficiently and to effectively launch ETFs and to optimize growth potential in a highly competitive space. For more information, visit https://www.tidalfinancialgroup.com/.

About ZEGA Financial

Founded in 2011, ZEGA Financial is a SEC-registered investment adviser and investment manager that specializes in derivatives. The firm leverages technology, data, experience, and proprietary strategies to craft products and services for advisors and individual investors. ZEGA Financial helps investors successfully navigate volatile and uncertain markets through innovative hedging strategies. The firm’s founding principles grew out of the bestselling book co-authored by Jay Pestrichelli, ZEGA’s CEO and Co-Founder, entitled “Buy and Hedge, the Five Iron Rules for Investing Over the Long Term.” His book highlights how to bridge the complicated nature of options investing with the needs of the everyday investor.

Risk Disclosures

Investing involves risk. Principal loss is possible. MRNA Risk. The Fund invests in options contracts that are based on the value of MRNA. This subjects the Fund to certain of the same risks as if it owned shares of MRNA, even though it does not. Call Writing Strategy Risk. The path dependency (i.e., the continued use) of the Fund's call writing strategy will impact the extent that the Fund participates in the positive price returns of MRNA and, in turn, the Fund's returns, both during the term of the sold call options and over longer time periods. Counterparty Risk. The Fund is subject to counterparty risk by virtue of its investments in options contracts. Transactions in some types of derivatives, including options, are required to be centrally cleared ("cleared derivatives"). In a transaction involving cleared derivatives, the Fund's counterparty is a clearing house rather than a bank or broker. Since the Fund is not a member of clearing houses and only members of a clearing house ("clearing members") can participate directly in the clearing house, the Fund will hold cleared derivatives through accounts at clearing members. Derivatives Risk. Derivatives are financial instruments that derive value from the underlying reference asset or assets, such as stocks, bonds, or funds (including ETFs), interest rates or indexes. The Fund’s investments in derivatives may pose risks in addition to, and greater than, those associated with directly investing in securities or other ordinary investments, including risk related to the market, imperfect correlation with underlying investments or the Fund’s other portfolio holdings, higher price volatility, lack of availability, counterparty risk, liquidity, valuation and legal restrictions. Options Contracts. The use of options contracts involves investment strategies and risks different from those associated with ordinary portfolio securities transactions. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in the value of the underlying instrument, including the anticipated volatility, which are affected by fiscal and monetary policies and by national and international political, changes in the actual or implied volatility or the reference asset, the time remaining until the expiration of the option contract and economic events. Distribution Risk. As part of the Fund’s investment objective, the Fund seeks to provide current monthly income. There is no assurance that the Fund will make a distribution in any given month. If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next. Call Writing Strategy Risk. The path dependency (i.e., the continued use) of the Fund’s call writing strategy will impact the extent that the Fund participates in the positive price returns and, in turn, the Fund’s returns, both during the term of the sold call options and over longer time periods. High Portfolio Turnover Risk. The Fund may actively and frequently trade all or a significant portion of the Fund’s holdings. Liquidity Risk. Some securities held by the Fund, including options contracts, may be difficult to sell or be illiquid, particularly during times of market turmoil. Non-Diversification Risk. Because the Fund is “non-diversified,” it may invest a greater percentage of its assets in the securities of a single issuer or a smaller number of issuers than if it was a diversified fund. New Fund Risk. The Fund is a recently organized management investment company with no operating history. As a result, prospective investors do not have a track record or history on which to base their investment decisions. Price Participation Risk. The Fund employs an investment strategy that includes the sale of call option contracts, which limits the degree to which the Fund will participate in increases in value experienced by MRNA over the Call Period. Single Issuer Risk. Issuer-specific attributes may cause an investment in the Fund to be more volatile than a traditional pooled investment which diversifies risk or the market generally. The value of the Fund, which focuses on an individual security (ARKK, TSLA, AAPL, NVDA, AMZN, META, GOOGL, NFLX, COIN, MSFT, DIS, XOM, JPM, AMD, PYPL, SQ, MRNA), may be more volatile than a traditional pooled investment or the market as a whole and may perform differently from the value of a traditional pooled investment or the market as a whole.

Investors in the Fund(s) will not have rights to receive dividends or other distributions with respect to the underlying stock.

Holdings

As of October 23, 2023, no YieldMax™ ETF held any shares of Moderna, Inc. (MRNA). The holdings of MRNA were 0.00% as of such date.

YieldMax™ ETFs are distributed by Foreside Fund Services, LLC. Foreside is not affiliated with Tidal Financial Group, YieldMax™ ETFs or ZEGA Financial.

© 2023 YieldMax™ ETFs 

 

Contact Data